Examining the European Pharma legislation: EFPIA publishes the Dolon Report

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation will negatively impact research and development in the pharmaceutical industry in Europe, potentially impacting the lives of patients around the world.  Below are some of the projected outcomes if the legislation is adopted.

Find out more about the potential impact: read EFPIA’s press release here and the full report here.